Menu Search
Equities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

1349:HKG.HS

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Actions
  • Price (HKD)2.79
  • Today's Change-0.09 / -3.13%
  • Shares traded2.50m
  • 1 Year change+8.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 06:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)745.47m
  • Net income in HKD113.40m
  • Incorporated1996
  • Employees948.00
  • Location
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdZhangjiang Hi-tech ParkNo.308 Cailun RoadPudong District, Zhangjiang Hi-tech ParkSHANGHAI 201210ChinaCHN
  • Phone+86 2 158553583
  • Fax+86 2 158553893
  • Websitehttp://www.fd-zj.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.